That will be an impressive milestone. That will mean it is on a lot of people's radar screens.
Looks like of day traders have been attracted to TAPM now. I was holder from $1 - $2 last year. I have dabbled since. But I have been out of TAPM waiting for a move out of its range bound area.
Now that it is above .30 and volume is up, I expect the trend to stay for the forseeable future. I think $10 is a realistic pps in the 1-2 years. Near term, I look for an easy trade above $1 soon, and $2 in the next 1-2 months.
GBSN has almost traded its float again in the first half hour. Nothing but day traders, shorts, and panic sellers here this morning.
TAPM finally moved out of a tight trading range and popped above a couple of "weak" resistance points.
Looking at the 1 year chart, no serious resitance before .80. It will be interesting to see what happens in the next couple of weeks.
Beat earnings by .02 and the revenue increase was a very nice beat. This is a pleasant surprise. Movement over the last month implied a miss. It will be interesting to see how this mover tomorrow.
A stock like ANFI with a low daily trading volume and low float is easy for MMs to manipulate. Throw a few scares out there and bingo, shorts get there way.
yep, the Bid/Ask sizes are pretty small. So someone is playing with this stock until they get the price they want.
Another reason to buy is Blueberry showed up. Once this ambulance chaser shows up, it is a sure sign to go the opposite. lol
This down draft in KPTI appears to be a great entry point. AML have a high incident for sepsis in the first place. The 8 patients who did get sepsis could be in the normal range. Changing dosage in clinical trial is pretty typical.
Fluidigm weakness a buying opportunity, says Leerink
Mizuho maintains neutral rating but Fluidigm price target lowered to $15
TNET has a low float and is also thinly traded (typically). This contributed to the exaggerated move at the open.
TriNet shares to be down more than 15%, says JPMorgan (no s##t)
JPMorgan expects shares of TriNet to be down more than the 2015 EBITDA guidance cut of 15% given management credibility concerns following the company's Q2 miss. It lowered its price target for shares to $24 from $39 but keeps an Overweight rating on the stock. TriNet continues to post solid underlying unit growth, JPMorgan points out.
With a Forward P/E now at 15.17 and PEG Ratio at 1.00, SWI is now at a very attractive entry point. The low daily volume explains the exaggerated move this morning.
Also, SWI is trading 20-30% below NEW target prices.
I almost pulled the trigger last night in AH around 42. Glad I waited.